Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Given Average Recommendation of “Hold” by Brokerages

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) has received an average recommendation of “Hold” from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $1.3517.

Several research firms have recently issued reports on ADAP. Mizuho lowered Adaptimmune Therapeutics from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $1.50 to $0.50 in a research report on Thursday, June 26th. Guggenheim cut shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 29th. Finally, HC Wainwright reissued a “neutral” rating on shares of Adaptimmune Therapeutics in a report on Tuesday, July 29th.

Adaptimmune Therapeutics Stock Up 22.8%

Shares of Adaptimmune Therapeutics stock opened at $0.08 on Friday. The company has a quick ratio of 1.29, a current ratio of 1.52 and a debt-to-equity ratio of 4.24. Adaptimmune Therapeutics has a 12 month low of $0.04 and a 12 month high of $1.09. The business has a fifty day simple moving average of $0.12 and a 200 day simple moving average of $0.23. The stock has a market cap of $21.68 million, a PE ratio of -0.13 and a beta of 2.24.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. The business had revenue of $13.68 million during the quarter, compared to analysts’ expectations of $11.04 million. Adaptimmune Therapeutics had a negative return on equity of 163.73% and a negative net margin of 260.82%. Research analysts predict that Adaptimmune Therapeutics will post -0.14 EPS for the current year.

Insider Transactions at Adaptimmune Therapeutics

In other Adaptimmune Therapeutics news, Director Ali Behbahani sold 14,671,794 shares of the business’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $0.01, for a total value of $146,717.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 19,803,000 shares of company stock valued at $198,030 over the last ninety days. 12.44% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Two Sigma Investments LP grew its position in shares of Adaptimmune Therapeutics by 33.5% in the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 19,146 shares during the period. Two Sigma Advisers LP boosted its holdings in shares of Adaptimmune Therapeutics by 492.0% in the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 58,787 shares during the period. Jane Street Group LLC boosted its holdings in shares of Adaptimmune Therapeutics by 87.7% in the fourth quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 152,780 shares during the period. Empirical Finance LLC acquired a new position in shares of Adaptimmune Therapeutics in the second quarter valued at approximately $192,000. Finally, Acadian Asset Management LLC boosted its stake in Adaptimmune Therapeutics by 334.8% in the 1st quarter. Acadian Asset Management LLC now owns 2,218,215 shares of the biotechnology company’s stock worth $424,000 after purchasing an additional 1,707,999 shares during the period. 31.37% of the stock is currently owned by institutional investors and hedge funds.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.